Inhibition of MG-63 cell cycle progression by synthetic vitamin D3 analogs mediated by p27, Cdk2, cyclin E, and the retinoblastoma protein

Biochemical Pharmacology

Volumn 66, Issue 3, 2003, Pages 495-504

  Ryhänen, Sanna ^a   Jääskeläinen, Tiina ^a   Mahonen, Anitta ^a   Mäenpää, Pekka H ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cdk2; Cell cycle; Cyclin E; Osteoblastic cells; p27; Rb; Vitamin D analogs

Indexed keywords

20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; CALCITRIOL; COLECALCIFEROL DERIVATIVE; CYCLIN DEPENDENT KINASE 2; CYCLIN E; LEXACALCITOL; PROTEIN P27; RETINOBLASTOMA PROTEIN; SEOCALCITOL;

ARTICLE; CELL ACTIVITY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; GENE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY;

EID: 0041695540     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00283-1     Document Type: Article

References (50)

1. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., Thompson P.D., Selznick S.H., Dominguez C.E., Jurutka P.W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13:1998;325-349.
2. Brown A.J. Therapeutic uses of vitamin D analogues. Am. J. Kidney Dis. 38:2001;S3-19.
3. 3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 53:1993;3712-3718.
4. 3: towards an endocrine therapy of brain tumours? J. Neurosci. Res. 37:1994;271-277.
5. 3 on primary cultures of human prostatic cells. Cancer Res. 54:1994;805-810.
6. Brenner R.V., Shabahang M., Schumaker L.M., Nauta R.J., Uskokovic M.R., Evans S.R., Buras R.R. The antiproliferative effect of vitamin D analogues on MCF-7 human breast cancer cells. Cancer Lett. 92:1995;77-82.
7. 3 in human malignant melanoma cell lines. J. Surg. Res. 61:1996;127-133.
8. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 16:1995;200-257.
9. Norman A.W. The vitamin D endocrine system: manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. J. Cell Biochem. 22(Suppl.):1995;218-225.
10. 3 analog KH1060. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10685-10690.
11. Jääskeläinen T., Ryhänen S., Mahonen A., DeLuca H.F., Mäenpää P.H. Mechanism of action of superactive vitamin D analogs through regulated receptor degradation. J. Cell Biochem. 76:2000;548-558.
12. 3 and the regulation of human cancer cell replication. Proc. Soc. Exp. Biol. Med. 191:1989;221-226.
13. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 55:1995;2822-2830.
14. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 139:1998;1197-1207.
15. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem. J. 308:1995;697-711.
16. Grana X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDIs). Oncogene. 11:1995;211-219.
17. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
18. 1-phase progression. Genes Dev. 13:1999;1501-1512.
19. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10:1996;142-153.
20. 3 in HL60 cells. Cancer Res. 56:1996;264-267.
21. 1-S phase-controlling machinery. Mol. Endocrinol. 15:2001;1370-1380.
22. 3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 58:1996;367-376.
23. 3 analogue shows relation to promoter selectivity. J. Cell Biochem. 66:1997;552-562.
24. 3-resistant variant. Endocrinology. 138:1997;4690-4698.
25. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994;81750-8.
26. Mahonen A., Jääskeläinen T., Mäenpää P.H. A novel vitamin D analog with two double bonds in its side chain. A potent inducer of osteoblastic cell differentiation. Biochem. Pharmacol. 51:1996;887-892.
27. Ryhänen S., Mahonen A., Jääskeläinen T., Mäenpää P.H. Synthetic 20-epi analogs of calcitriol are potent inducers of target-gene activation in osteoblastic cells. Eur. J. Biochem. 238:1996;97-103.
28. 3 analog with an extensively modified side chain (CB1093). J. Cell Biochem. 70:1998;414-424.
29. 3 analogs. Eur. J. Biochem. 261:1999;706-713.
30. Hurst H.C., Masson N., Jones N.C., Lee K.A.W. The cellular transcription factor CREB corresponds to activating transcription factor 47 (ATF-47) and forms complexes with a group of polypeptides related to ATF-43. Mol. Cell Biol. 10:1990;6192-6203.
31. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiosyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
32. Kip1 gene promoter that lacks vitamin D response elements. J. Biol. Chem. 274:1999;32309-32317.
33. Gu Y., Rosenblatt J., Morgan D.O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 11:1992;3995-4005.
34. Polyak K., Lee M.H., Erdjument-Bromage H., Koff A., Roberts J.M., Tempst P., Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66.
35. 1-S phase protein kinase. Science. 257:1992;1958-1961.
36. 1 control in retinoblastoma gene-deficient cells independently of Cdk4 activity. Mol. Cell Biol. 15:1995;2600-2611.
37. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
38. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat. 42:1997;31-41.
39. 1. Endocrinology. 138:1997;1491-1497.
40. 3 in cultured human epidermal keratinocytes. J. Invest. Dermatol. 109:1997;46-54.
41. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14:2000;2393-2409.
42. Hengst L., Reed S.I. Translational control of p27 accumulation during the cell cycle. Science. 271:1996;1861-1864.
43. 3 analogue involves the induction of p21(Waf1), p27(Kip1) and E-cadherin. J. Mol. Endocrinol. 19:1997;15-27.
44. 1, p21 and p27 in MCF-7 cells. Mol. Cell Endocrinol. 142:1998;57-65.
45. 1 that in preceded by a transient proliferative burst and increase in cyclin expression. Blood. 93:1999;2721-2729.
46. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., Yew P.R., Draetta G.F., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
47. Liu W., Asa S.L., Fantus I.G., Walfish P.G., Ezzat S. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/Akt-dependent and -independent pathways. Am. J. Pathol. 160:2002;511-519.
48. Jackson S.P., MacDonald J.J., Lees-Miller S., Tjian R. GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase. Cell. 63:1990;155-165.
49. Jackson S.P., Tjian R. O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell. 55:1988;125-133.
50. Park W.H., Seol J.G., Kim E.S., Jung C.W., Lee C.C., Binderup L., Koeffler H.P., Kim B.K., Lee Y.Y. Cell cycle arrest induced by the vitamin D analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Exp. Cell Res. 254:2000;279-286.